RECOMBINANT DNA TECHNOLOGY MARKET ANALYSIS

Key Developments

• On January 24, 2024, Core Biogenesis, a biotechnology company, and Nucleus Biologics, provider of custom cell-growth media, tools, and technologies for cell and gene therapy, announced a collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
• In March 2022, ProteoGenix, a contract research organization specialized in biologics discovery and bioproduction, announced the launch of launch of its XtenCHO Transient Expression System. The new CHO host aims to simplify recombinant protein production and accelerate early phase drug screening.
• In January 2022, Jiangsu Recbio Technology Co., Ltd. (Recbio), a biopharmaceutical company focusing on the research and development of new corona vaccine, developed Recombinant COVID-19 Vaccine ReCOV and announced the authorization of ReCOV in The Philippines after Phase 1 studies get strong immunogenicity and safety data, as well as good cross-neutralization against Volatile Organic Compounds (VOCs) such as Omicron and Delta.
• In January 2022, Thermo Fisher Scientific Inc., a global biotechnology company, announced the acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering
• In June 2020, Lonza, a global healthcare company, announced that they had expanded its cell culture media portfolio with the addition of the GSv9 Media and Feeds, providing a fully integrated solution specifically designed to optimize recombinant protein production using Lonza’s GS Gene Expression System